Propylene Glycol

Propylene Glycol

SCHEMBL251122

CC(N)COCC(C)N.CC(N)COCC(C)N.CC(O)CO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.53
HSD17B10 Q99714 1/20 0.37
TSHR P16473 4/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 2/20 0.32
SCN4A P35499 3/20 0.30
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
NFKB1 P19838 1/20 0.30
KCNK3 O14649 1/20 0.30
CACNA1F O60840 1/20 0.30
KCNK2 O95069 1/20 0.30
GBA1 P04062 1/20 0.30
MAOA P21397 1/20 0.30
HTR2A P28223 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propylene Glycol SCHEMBL27811556 1.00 TDP1 (0.53) TDP1HSD17B10TSHRMAPK1ALDH1A1
Propylene Glycol SCHEMBL6567284 1.00 TDP1 (0.53) TDP1HSD17B10TSHRMAPK1ALDH1A1
SCHEMBL7011240 0.86
Ethylene Glycol SCHEMBL450520 0.83 ALDH1A1 (0.35) TSHRMAPK1ALDH1A1SCN4ALMNA
Ethylene Glycol SCHEMBL2723632 0.83 ALDH1A1 (0.35) TSHRMAPK1ALDH1A1SCN4ALMNA
SCHEMBL114351 0.83
SCHEMBL30985226 0.83
SCHEMBL19654931 0.78 TP53 (0.35) TDP1TSHR
Propylene Glycol SCHEMBL535998 0.78 TDP1 (0.59) TDP1HSD17B10TSHRMAPK1ALDH1A1
Di(Hydroxyethyl)Ether SCHEMBL14054643 0.77 TSHR (0.50) HSD17B10TSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098123-A1 LIGNIN-DERIVED CURING AGENTS, AS WELL AS THEIR USE IN RESIN COMPOSITIONS AND METHOD FOR PREPARING SAID LIGNIN-DERIVED CURING AGENTS VITO NV (BE) 2026-04-09 US claimed
US-12469851-B2 Anode protective layer for lithium-sulfur cells Lyten, Inc. (US) 2025-11-11 US claimed
EP-3774992-B9 POLYMERIC MATERIALS AND ARTICLES MANUFACTURED THERE FROM PROCTER & GAMBLE (US) 2025-10-22 EP claimed
EP-3774992-B1 POLYMERIC MATERIALS AND ARTICLES MANUFACTURED THERE FROM PROCTER & GAMBLE (US) 2025-09-03 EP claimed
US-12338322-B2 Photo-responsive dampening and toughening agents THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2025-06-24 US claimed
WO-2024263666-A1 CURABLE COMPOSITIONS WITH LOW EXOTHERM HENKEL AG & CO. KGAA (DE) 2024-12-26 WO claimed
US-11958253-B2 Use of isosorbide ELANTAS EUROPE S.R.L. (IT) 2024-04-16 US claimed
US-11951449-B2 Method for preparing organic-inorganic hybrid microcapsule LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2024-04-09 US claimed
US-11955603-B2 Composite electrolytes QUANTUMSCAPE BATTERY, INC. (US) 2024-04-09 US claimed
WO-2024068653-A1 LIGNIN-DERIVED CURING AGENTS, AS WELL AS THEIR USE IN RESIN COMPOSITIONS AND METHOD FOR PREPARING SAID LIGNIN-DERIVED CURING AGENTS VITO NV (BE) 2024-04-04 WO claimed
WO-2006127570-A2 POLYPROPYLENE SILICATE NANOCOMPOSITES CORNELL RESEARCH FOUNDATION, INC. (US) 2006-11-30 WO claimed
US-20060260677-A1 Polypropylene silicate nanocomposites CORNELL RESEARCH FOUNDATION, INC. (US) 2006-11-23 US claimed
WO-2006063442-A1 SILICA-FILLED ELASTOMERIC COMPOUNDS LANXESS INC. (CA) 2006-06-22 WO claimed
WO-2005111116-A1 BIOLOGICAL MOLECULE-REACTIVE HYDROPHILIC SILICONE SURFACE MCMASTER UNIVERSITY (CA) 2005-11-24 WO claimed
EP-1542926-A1 METHODS AND COMPOUNDS FOR CONTROLLING THE MORPHOLOGY AND SHRINKAGE OF SILICA DERIVED FROM POLYOL-MODIFIED SILANES McMaster University (CA) 2005-06-22 EP claimed
US-20040249082-A1 Protein compatible methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes MCMASTER UNIVERSITY (CA) 2004-12-09 US claimed
US-20040211730-A1 Methods and compounds for controlling the morphology and shrinkage of silica derived from polyol-modified silanes ZHANG ZHENG 2004-10-28 US claimed
US-6784274-B2 FOR REDUCING THE ELECTRODE IMPEDANCE OF IMPLANTABLE BIOSENSORS; COATING OF A HYDROGEL FORMED FROM A DIISOCYANATE, A HYDROPHILIC POLYMER SELECTED FROM A POLYOXYETHYLENE GLYCOL AND JEFFAMINES?, AND A CHAIN EXTENDER MINIMED INC. 2004-08-31 US claimed
WO-2004018360-A1 METHODS AND COMPOUNDS FOR CONTROLLING THE MORPHOLOGY AND SHRINKAGE OF SILICA DERIVED FROM POLYOL-MODIFIED SILANES MCMASTER UNIVERSITY (CA) 2004-03-04 WO claimed
US-6462162-B2 REDUCING ELECTRODE IMPEDANCE OF IMPLANTABLE BIOSENSORS BY COATING THE SURFACE WITH UNIFORM HYDROGEL (POLYUREA, POLYURETHANE) WHICH ALLOWS UNIMPEDED WATER MOVEMENT MINIMED INC. 2002-10-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098123-A1 LIGNIN-DERIVED CURING AGENTS, AS WELL AS THEIR USE IN RESIN COMPOSITIONS AND METHOD FOR PREPARING SAID LIGNIN-DERIVED CURING AGENTS EHMT1, SRM, EHMT2 TDP1 1797/4885HSD17B10 4664/4885TSHR 4693/4885
US-11951449-B2 Method for preparing organic-inorganic hybrid microcapsule INCENP, PHOSPHO1, CHMP4B TDP1 3015/4885HSD17B10 4478/4885TSHR 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.